Rifampicin, cisapride, pimozide, quinidine, bepridil, triazolam, tadalafil, sildenafil, midazolam,

Ergot alkaloids , St, Johns Wart.

Hepatitis B or C antiviral therapy

PR or QT prolongation agents

Pacilitaxel , OCs

 ritonavir, tenofovir, efavirenz, nervirapine, indinavir, Didanosine, saquinavir,

statins, Trazolodone opiods, H2 antagonists

Jaundice, GI upset, abdominal pain, headache,

insomnia, asthenia,

Fatigue, peripheral neuropathy,

Rash, dizziness, myalgia,

Fever, pancreatitis

Raised bilirubin and liver enzymes

Nephrolithiasis,

Gall bladder disorders,lactic acidosis

Diabetes , depression

Fat distribution

Prolonged PR intervaL

Concurrent admin of rifampicin, irinotecan Midazolam, ergots, statins

Cisapride, St.Johns wart, Pimozide, indinavir, alfuzosin

Hepatic impairment

Pregnancy

Lactation

Special precauions-

Risk of lactic acidosis ( female obesity )

Monitor liver functions History of Hepatitis B , 

Cardiac conduction disturbance disturbances Risk factors for QT prolongation

Monitor fasting serum lipids and blood glucose

Risk of immune reactivation syndrome within first few weeks or Months after starting ARV therapy

Monitor for signs of joint pain or immobility

Indication-

With other antivirals to treat HIV infections

Dosage-

300mg once daily with ritonavir taken withn food. if didanosine is co-administered with this combination , take it 2 hrs later.

Children - not recommended

 PATIENT COUNSELING INFORMATION

See FDA-approved patient labeling (Patient Information).

A statement to patients and healthcare providers is included on the product’s bottle label: ALERT: Find out about medicines that should NOT be taken with REYATAZ.

Patients should be informed that REYATAZ is not a cure for HIV infection and that they may continue to develop opportunistic infections and other complications associated with HIV disease.

Patients should be told that there are currently no data demonstrating that therapy with REYATAZ can reduce the risk of transmitting HIV to others through sexual contact. 

Patients should be told that sustained decreases in plasma HIV RNA have been associated with a reduced risk of progression to AIDS and death.

Patients should remain under the care of a Approved  while using REYATAZ.

Patients should be advised to take REYATAZ with food every day and take other concomitant antiretroviral therapy as prescribed. REYATAZ must always be used in combination with other antiretroviral drugs.

Patients should not alter the dose or discontinue therapy without consulting with their doctor. If a dose of REYATAZ is missed, patients should take the dose as soon as possible and then return to their normal schedule. However, if a dose is skipped the patient should not double the next dose.

 Drug Interactions-                                                                                                REYATAZ may interact with some drugs; therefore, patients should be advised to report to their doctor the use of any other prescription, nonprescription medication, or herbal products, particularly St. John’s wort.

Patients receiving a PDE5 inhibitor and atazanavir should be advised that they may be at an increased risk of PDE5 inhibitor-associated adverse events including hypotension, syncope, visual disturbances, and priapism, and should promptly report any symptoms to their doctor.

Take with food
 

Use contraindicated,

Observe caution if required to be administered